In cancer, how much medication is too much medication? Patients and researchers question doses approved by the FDA

The question of oncology drug doses is generating debate among patients and researchers. Pembrolizumab is normally prescribed at a fixed dose, while nivolumab is sometimes prescribed in a fixed manner and other times based on the patient's weight. This inconsistency in how drugs are dosed raises questions about the appropriateness of the doses approved by the FDA. Patients and researchers are questioning whether the currently approved doses are really the most appropriate for cancer treatment. When a patient receives a dose lower than indicated on the label, drug manufacturers generally receive less money. However, they are not the only ones affected by this situation. The article suggests that there are additional losses that go beyond the financial impact on pharmaceutical companies, although it does not specify what these losses are.